Clinical Trials
22 trialsNCT07619521 2026-06-02
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT02151084 2025-12-16
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT02188264 2025-02-11
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01160926 2023-04-24
DREAMtherapy
The Christie NHS Foundation Trust
Phase 1 Terminated
NCT01134601 2021-12-01
A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01222689 2020-07-31
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01287130 2019-12-17
AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02586987 2019-11-18
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02450656 2018-08-27
M14AFS
The Netherlands Cancer Institute
Phase 1/2 Unknown
NCT01242605 2016-05-13
ABC-04
University College, London
Phase 1 Completed
NCT01949870 2016-05-13
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
AstraZeneca
Phase 1 Terminated
NCT00553332 2016-04-22
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01658943 2016-03-09
S1115
National Cancer Institute (NCI)
Phase 2 Completed
NCT01333475 2015-09-30
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01029418 2015-04-16
AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
National Cancer Centre, Singapore
Phase 1/2 Terminated
NCT01859182 2014-09-09
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00372944 2014-08-13
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
AstraZeneca
Phase 2 Completed
NCT00514761 2014-08-13
Phase II Efficacy Study of AZD6244 in Colorectal Cancer
AstraZeneca
Phase 2 Completed
NCT01217450 2014-05-29
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00604721 2014-05-28
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01116271 2013-01-14
Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
AstraZeneca
Phase 2 Completed